A Phase 2 interventional study of Brentuximab Vedotin and Laboratory Biomarker Analysis in Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma and Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, sponsored by John Reneau. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by John Reneau · Phase 2, Interventional, and Treatment
This phase II trial studies how well brentuximab vedotin and lenalidomide work in treating patients with stage IB-IVB T-cell lymphoma that have come back or do not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and lenalidomide may work better in treating patients with T-cell lymphoma.
PRIMARY OBJECTIVES:
I. To determine the overall response rate (ORR) of the combination of brentuximab vedotin (BV) and lenalidomide in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL)/peripheral T-cell lymphoma (PTCL).
SECONDARY OBJECTIVES:
I. To estimate the duration of response and 2 year progression-free survival (PFS) and overall survival (OS) associated with the combination of brentuximab vedotin (BV) and lenalidomide in patients with relapsed or refractory CTCL/PTCL.
II. To define the qualitative and quantitative toxicities of the combination of brentuximab vedotin (BV) and lenalidomide in patients with relapsed or refractory CTCL/PTCL.
TERTIARY OBJECTIVES:
I. To correlate between the expression of CD30 in neoplastic cells by immunohistochemistry (IHC) and overall response rate (ORR) of the combination of brentuximab vedotin (BV) and lenalidomide in patients with relapsed or refractory CTCL/PTCL.
II. To determine T-cell and natural killer (NK) cell subset numbers, phenotype, and functional status in relapsed or refractory (rel/ref) CTCL/PTCL patients, and whether the combination of brentuximab vedotin and lenalidomide alters these parameters during therapy.
III. To determine changes in plasma cytokine levels and other biomarkers in this patient population during therapy with the combination of brentuximab vedotin and lenalidomide.
OUTLINE:
Patients receive brentuximab vedotin intravenously (IV) over 30 minutes on day 1 and lenalidomide orally (PO) once daily (QD) on day 1-21. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years.
554 studies on the registry are indexed under Lymphoma, T-Cell, Cutaneous; 63 are open to participants now.
This study's enrollment of 26 is below the median of 35 across 405 interventional studies indexed under Lymphoma, T-Cell, Cutaneous.
Browse Lymphoma, T-Cell, Cutaneous studies →John Reneau is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-proven, measurable, stage IB-IVB cutaneous T-cell lymphoma after 2 lines of skin-directed therapy or one
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on day 1-21. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
Drug: Brentuximab Vedotin · Other: Laboratory Biomarker Analysis · Drug: Lenalidomide
Given IV
Also known as: ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35
Correlative studies
Given PO
Also known as: CC-5013, CC5013, CDC 501, Revlimid
Overall Response Rate
The overall response rate (ORR) of the combination of brentuximab vedotin (BV) and lenalidomide in patients with relapsed or refractory CTCL/PTCL. . ORR is defined as the proportion of patients who achieve complete response (CR) or partial response (PR). Response (CR, PR, SD) and progression will be defined using the Global Response Score
Time frame: Up to 2 years
Incidence of Adverse Events According to National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.0
Toxicity will be graded by the NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0
Time frame: Up to 30 days after last day of study treatment
Overall Survival (OS)
Kaplan-Meier method will be used to estimate OS.
Time frame: From start of study treatment to date of death due to any cause, assessed up to 2 years
Progression Free Survival (PFS)
Kaplan-Meier method will be used to estimate PFS.
Time frame: From start of study treatment to first documentation of tumor progression (including radiographic and clinical progression) or to death due to any cause, whichever comes first, assessed up to 2 years
| Milestone | Treatment (Brentuximab Vedotin, Lenalidomide) |
|---|---|
| Started | 26 |
| Completed | 22 |
| Not completed | 4 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Disease progression | 1 |
The overall response rate (ORR) of the combination of brentuximab vedotin (BV) and lenalidomide in patients with relapsed or refractory CTCL/PTCL. . ORR is defined as the proportion of patients who achieve complete response (CR) or partial response (PR). Response (CR, PR, SD) and progression will be defined using the Global Response Score
| Percentage of participants | Treatment (Brentuximab Vedotin, Lenalidomide) |
|---|---|
| Overall Response Rate | 34.6 (17.2 to 55.7) |
Toxicity will be graded by the NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0
| Number of participants | Treatment (Brentuximab Vedotin, Lenalidomide) |
|---|---|
| Diarrhea | 14 |
| Lymphocyte count decreased | 12 |
| Anemia | 11 |
| White blood cell decreased | 11 |
| Neutrophil count decreased | 10 |
| Rash maculo-papular | 10 |
| Fatigue | 9 |
| Aspartate aminotransferase increased | 8 |
| Nausea | 8 |
| Peripheral sensory neuropathy | 8 |
| Platelet count decreased | 7 |
| Abdominal pain | 6 |
| Constipation | 6 |
| Edema limbs | 6 |
| Myalgia | 5 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify | 5 |
| Pruritus | 5 |
| Alkaline phosphatase increased | 4 |
| Anorexia | 4 |
| Malaise | 4 |
| Vomiting | 4 |
| Alanine aminotransferase increased | 3 |
| Dizziness | 3 |
| Dysgeusia | 3 |
| Gastrointestinal disorders - Other, specify | 3 |
| Musculoskeletal and connective tissue disorder - Other, specify | 3 |
| Skin and subcutaneous tissue disorders - Other, specify | 3 |
| Weight loss | 3 |
| Blood bilirubin increased | 2 |
| Fever | 2 |
| Hyperglycemia | 2 |
| Hypoalbuminemia | 2 |
| Hypokalemia | 2 |
| Hypomagnesemia | 2 |
| Hypothyroidism | 2 |
| Infusion related reaction | 2 |
| Pain | 2 |
| Pain in extremity | 2 |
| Skin hyperpigmentation | 2 |
| Stomach pain | 2 |
| Thromboembolic event | 2 |
| Allergic rhinitis | 1 |
| Alopecia | 1 |
| Bloating | 1 |
| Bruising | 1 |
| CD4 lymphocytes decreased | 1 |
| Colitis | 1 |
| Creatinine increased | 1 |
| Depression | 1 |
| Dyspepsia | 1 |
| Dyspnea | 1 |
| Fall | 1 |
| Fracture | 1 |
| Gait disturbance | 1 |
| General disorders and administration site conditions - Other, specify | 1 |
| Generalized muscle weakness | 1 |
| Headache | 1 |
| Hoarseness | 1 |
| Hot flashes | 1 |
| Hyperhidrosis | 1 |
| Hypocalcemia | 1 |
| Hypoglycemia | 1 |
| Hypotension | 1 |
| Immune system disorders - Other, specify | 1 |
| Infections and infestations - Other, specify | 1 |
| Lung infection | 1 |
| Muscle weakness lower limb | 1 |
| Paresthesia | 1 |
| Portal vein thrombosis | 1 |
| Respiratory, thoracic and mediastinal disorders - Other, specify | 1 |
| Skin infection | 1 |
| Skin ulceration | 1 |
| Urinary tract infection | 1 |
| Vertigo | 1 |
| Weight gain | 1 |
Kaplan-Meier method will be used to estimate OS.
| Months | Treatment (Brentuximab Vedotin, Lenalidomide) |
|---|---|
| Overall Survival (OS) | 22.6 (11.7 to 42.8) |
Kaplan-Meier method will be used to estimate PFS.
| Months | Treatment (Brentuximab Vedotin, Lenalidomide) |
|---|---|
| Progression Free Survival (PFS) | 6.7 (2.9 to 19.9) |
Collected over Assessed up to 2 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment (Brentuximab Vedotin, Lenalidomide) | 16/26 (61.5%) | 7/26 (26.9%) | 26/26 (100%) |
| Event | Treatment (Brentuximab Vedotin, Lenalidomide) |
|---|---|
| ColitisGastrointestinal disorders | 1/26 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/26 |
| FeverGeneral disorders and administration site conditions | 1/26 |
| FractureInjury, poisoning and procedural complications | 1/26 |
| Lung infectionInfections and infestations | 1/26 |
| Portal vein thrombosisHepatobiliary disorders | 1/26 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 1/26 |
| Respiratory, thoracic and mediastinal disorders - Other, specifyRespiratory, thoracic and mediastinal disorders | 1/26 |
| SepsisInfections and infestations | 1/26 |
| Skin and subcutaneous tissue disorders - Other, specifySkin and subcutaneous tissue disorders | 1/26 |
| Event | Treatment (Brentuximab Vedotin, Lenalidomide) |
|---|---|
| DiarrheaGastrointestinal disorders | 14/26 |
| Lymphocyte count decreasedInvestigations | 13/26 |
| AnemiaBlood and lymphatic system disorders | 12/26 |
| White blood cell decreasedInvestigations | 11/26 |
| HyperglycemiaMetabolism and nutrition disorders | 10/26 |
| HypoalbuminemiaMetabolism and nutrition disorders | 10/26 |
| Neutrophil count decreasedInvestigations | 10/26 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 10/26 |
| Edema limbsGeneral disorders and administration site conditions | 9/26 |
| FatigueGeneral disorders and administration site conditions | 9/26 |
| Age, Continuous(Years) | Treatment (Brentuximab Vedotin, Lenalidomide) |
|---|---|
| Median | 60 (37 to 90) |
| Sex: Female, Male(Participants) | Treatment (Brentuximab Vedotin, Lenalidomide) |
|---|---|
| Female | 8 |
| Male | 18 |
| Race (NIH/OMB)(Participants) | Treatment (Brentuximab Vedotin, Lenalidomide) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 21 |
| More than one race | 2 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Treatment (Brentuximab Vedotin, Lenalidomide) |
|---|---|
| United States | 26 |
| Prior Therapies(Number of prior therapies) | Treatment (Brentuximab Vedotin, Lenalidomide) |
|---|---|
| Median | 4.5 (1 to 9) |
| Histology and Stage(Participants) | Treatment (Brentuximab Vedotin, Lenalidomide) |
|---|---|
| Mycosis fungoides (MF) | 13 |
| Peripheral T-cell lymphomas (PTCL) | 8 |
| Sezary syndrome (SS) | 3 |
| CD30+ lymphoproliferative disorders (LPD) | 2 |
| CD30 Positive(Participants) | Treatment (Brentuximab Vedotin, Lenalidomide) |
|---|---|
| No | 4 |
| Yes | 18 |
| Unknown | 4 |
| Large cell transformation (only applicable to MF and SS)(Participants) | Treatment (Brentuximab Vedotin, Lenalidomide) |
|---|---|
| No | 7 |
| Yes | 5 |
| Unknown | 4 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brentuximab Vedotin · Lenalidomide